OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (Avivagen), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has signed a significant new purchase agreement to supply its largest customer in Asia with a 6.3 tonne order of OxC-beta Livestock. The shipment represents a 43% increase in size over the customers previous order and continues a trend of increased reorder size among this and other OxC-beta customers worldwide.
Were extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions worldwide for livestock feed production, says Kym Anthony, Chief Executive Officer, Avivagen Inc. We believe that the fact that Avivagens customers continue to increase order size for OxC-beta amid a global pandemic is a clear sign of the positive impact that integration of our products can have on our customers bottom line. Were excited by the growth potential ahead of us in both Asia and around the world.
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta Technology and OxC-beta Livestock
Avivagens OxC-beta technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.
Avivagens OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim, anticipate, appear, believe, consider, could, estimate, expect, if, intend, goal, hope, likely, may, plan, possibly, potentially, pursue, seem, should, whether, will, would and similar expressions. Statements set out in this news release relating to the future plans of Avivagens customers and the potential for additional and/or increased orders from such customers, anticipated growth in demand for Avivagens products, the anticipated date of fulfillment for the order described, the possibility for OxC-beta Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagens products, the customer plans may change due to many reasons, demand for Avivagens products may not continue to grow and could decline, Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or, in the worst case, cause the order to be terminated and the market opportunities may not be as large as Avivagen anticipates, in each case due to many factors, many of which are outside of Avivagens control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2021 Avivagen Inc. OxC-beta is a trademark of Avivagen Inc.
Contacts
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
HONG KONG SAR - Media OutReach Newswire - 8 November 2024 - ZJLD Group Inc.…
REACH, Singapore and Reggio Children, Italy present Mosaic of Marks, Words, Material SINGAPORE - Media…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 8 November 2024 - Trading offers a…
SINGAPORE - Media OutReach Newswire - 8 November 2024 - Home Action Party (HAP) is…
SINGAPORE - Media OutReach Newswire - 8 November 2024 - The Asia Pacific Enterprise Awards…
An iterative process is highly effective in increasing the value of large items HONG KONG…